Variation of serum monocyte chemoattractant protein-1 in patients with diabetes and metabolic syndrome

Abstract

This study investigated the variation of serum monocyte chemoattractant protein-1 (MCP-1) in patients with both diabetes mellitus (DM) and metabolic syndrome (MS). Based on the International Diabetes Federation (IDF) diagnostic criteria, 93 patients enrolled in this study were divided into four groups: normal control (NC), simple DM, simple MS, and DM plus MS (DM-MS) groups. The main measures included height, weight, waist circumference (WC), hip circumference, blood pressure, fasting blood glucose, insulin resistance index (HOMA-IR), serum triglyceride (TG), HDL-ch, LDL-ch, and MCP-1. The results showed that the serum levels of MCP-1 in the DM-MS group were significantly increased as compared with those in the DM and MS groups (P<0.05), and the increase in the MCP-1 level in the DM group was much higher than in the MS group (P<0.05). The DM-MS group had the highest HOMA-IR levels, followed by MS, DM and NC groups (P<0.05). Correlation tests showed that the association of MCP-1 with age, HDL-ch, or LDL-ch was insignificant, whereas that of MCP-1 with body mass index (BMI), waist hip rate (WHR), WC, systolic blood pressure (SBP), diastolic blood pressure (DBP), TG, and HOMA-IR was significantly positive. It was concluded that circulating MCP-1 was substantially increased in patients with both DM and MS as compared with that in the patients with DM or MS alone, and the central obese state may contribute to a more vicious proinflammatory condition and insulin resistance in patients with diabetes.

Keywords

monocyte chemoattractant protein-1 / diabetes / metabolic syndrome

References

[1] IsomaaB., AlmgrenP., TuomiT., et al.. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24(4): 683-689

[2] KleinB.E., KleinR., LeeK.E.. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care, 2002, 25(10): 1790-1794

[3] AlbertiK.G., ZimmetP., ShawJ.. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med, 2006, 23(5): 469-480

[4] BalkauB., CharlesM.A.. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med, 1999, 16(5): 442-443

[5] AlbertiK.G., ZimmetP.Z.. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15(7): 539-553

[6] Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA, 2001, 285(19): 2486–2497

[7] AlbertiK.G., ZimmetP., ShawJ.. The metabolic syndrome—a new worldwide definition. Lancet, 2005, 366(9491): 1059-1062

[8] TsubakimotoA., SaitoI., MannamiT., et al.. Impact of metabolic syndrome on brachial-ankle pulse wave velocity in Japanese. Hypertens Res, 2006, 29(1): 29-37

[9] MiyakiK., HaraA., NaitoM., et al.. Two new criteria of the metabolic syndrome: prevalence and the association with brachial-ankle pulse wave velocity in Japanese male workers. J Occup Health, 2006, 48(2): 134-140

[10] HaffnerS.M., LehtoS., RonnemaaT., et al.. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339(4): 229-234

[11] VaccaroO., EberlyL.E., NeatonJ.D., et al.. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med, 2004, 164(13): 1438-1443

[12] EvansJ.M., WangJ., MorrisA.D.. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ, 2002, 324(7343): 939-942

[13] AlexanderC.M., LandsmanP.B., TeutschS.M., et al.. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 2003, 52(5): 1210-1214

[14] WallaceT.M., MatthewsD.R.. The assessment of insulin resistance in man. Diabet Med, 2002, 19(7): 527-534

[15] DayC.. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res, 2007, 4(1): 32-38

[16] CaiD., YuanM., FrantzD.F., et al.. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 2005, 11(2): 183-190

[17] BugianesiE., McCulloughA.J., MarchesiniG.. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42(5): 987-1000

[18] HotamisligilG.S., ArnerP., CaroJ.F., et al.. Spiegelman, Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest, 1995, 95(5): 2409-2415

[19] ArkanM.C., HevenerA.L., GretenF.R., et al.. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med, 2005, 11(2): 191-198

[20] WeisbergS.P., HunterD., HuberR., et al.. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest, 2006, 116(1): 115-124

[21] KandaH., TateyaS., TamoriY., et al.. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 2006, 116(6): 1494-1505

[22] WeisbergS.P., McCannD., DesaiM., et al.. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest, 2003, 112(12): 1796-1808

[23] de LucaC., OlefskyJ.M.. Inflammation and insulin resistance. FEBS Lett, 2008, 582(1): 97-105

[24] BoringL., GoslingJ., ChensueS.W., et al.. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest, 1997, 100(10): 2552-2561

[25] GoslingJ., SlaymakerS., GuL., et al.. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest, 1999, 103(6): 773-778

[26] McDermottD.H., YangQ., KathiresanS., et al.. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation, 2005, 112(8): 1113-1120

[27] KameiN., TobeK., SuzukiR., et al.. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem, 2006, 281(36): 26 602-26 614

[28] SimeoniE., HoffmannM.M., WinkelmannB.R., et al.. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia, 2004, 47(9): 1574-1580

[29] KaurS., PanickerS.R., JamesT., et al.. Association of monocyte chemoattractant protein-1 -2518 polymorphism with metabolic syndrome in a South Indian cohort. Metab Syndr Relat Disord, 2009, 7(3): 193-198

[30] EckelR.H., GrundyS.M., ZimmetP.Z.. The metabolic syndrome. Lancet, 2005, 365(9468): 1415-1428

[31] EzenwakaC.E., NwagbaraE., SealesD., et al.. Insulin resistance, leptin and monocyte chemotactic protein-1 levels in diabetic and non-diabetic Afro-Caribbean subjects. Arch Physiol Biochem, 2009, 115(1): 22-27

[32] BlahaV., AndrysC., SmahelovaA., et al.. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res, 2006, 54(6): 421-428

[33] MineS., OkadaY., TanikawaT., et al.. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun, 2006, 344(3): 780-785

[34] MatthewsD.R., HoskerJ.P., RudenskiA.S., et al.. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28(7): 412-419

[35] KouyamaK., MiyakeK., ZenibayashiM., et al.. Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J Med Sci, 2008, 53(6): 345-354

[36] NakamuraK., YamagishiS., AdachiH., et al.. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev, 2008, 24(2): 109-114

[37] SakalliogluE.E., AyasB., LutfiogluM., et al.. Gingival levels of monocyte chemoattractant protein-1 (MCP-1) in diabetes mellitus and periodontitis: an experimental study in rats. Clin Oral Investig, 2008, 12(1): 83-89

[38] WangQ.Y., ChenF.Q.. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus. Diabetes Res Clin Pract, 2009, 83(2): 215-219

[39] SellH., Dietze-SchroederD., KaiserU., et al.. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology, 2006, 147(5): 2458-2467

[40] BruunJ.M., LihnA.S., VerdichC., et al.. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab, 2003, 285(3): E527-533

[41] ChristiansenT., RichelsenB., BruunJ.M.. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond), 2005, 29(1): 146-150

[42] BruunJ.M., LihnA.S., PedersenS.B., et al.. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab, 2005, 90(4): 2282-2289

[43] SartipyP., LoskutoffD.J.. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A, 2003, 100(12): 7265-7270

[44] TrøseidM., LappegardK.T., ClaudiT., et al.. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J, 2004, 25(4): 349-355

[45] CornierM.A., DabeleaD., HernandezT.L., et al.. The metabolic syndrome. Endocr Rev, 2008, 29(7): 777-822

[46] PickupJ.C.. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care, 2004, 27(3): 813-823

[47] HotamisligilG.S.. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord, 2003, 27(Suppl3): S53-55

[48] WisseB.E.. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol, 2004, 15(11): 2792-2800

[49] KimC.S., ParkH.S., KawadaT., et al.. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond), 2006, 30(9): 1347-1355